Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

269 results
Display

Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease

Han E, Lee Yh, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Lee BW, Kang ES, Cha BS, Kim SU

Background/Aims: Metabolic dysfunction associated fatty liver disease (MAFLD) has recently been introduced to compensate for the conventional concept of nonalcoholic fatty liver disease (NAFLD). We explored whether fibrotic burden determines...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Protective Effect of Delta-Like 1 Homolog Against Muscular Atrophy in a Mouse Model

Lee JY, Lee M, Lee DH, Lee Yh, Lee BW, Kang ES, Cha BS

Background: Muscle atrophy is caused by an imbalance between muscle growth and wasting. Delta-like 1 homolog (DLK1), a protein that modulates adipogenesis and muscle development, is a crucial regulator of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Improvement in Age at Mortality and Changes in Causes of Death in the Population with Diabetes: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018

Han E, Song SO, Kim HS, Son KJ, Jee SH, Cha BS, Lee BW

Background: Diabetes is a leading cause of death that is responsible for 1.6 million annual deaths worldwide. However, the life expectancy and age at death of people with diabetes have...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes

Bae J, Kim Ye, Lee M, Lee Yh, Lee BW, Cha BS, Kang ES

Purpose: To date, no study has compared the effects of adding sodium glucose cotransporter-2 (SGLT-2) inhibitors to the combination of metformin plus dipeptidyl peptidase-4 (DPP-4) inhibitors to the effects of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease

Kim Y, Han E, Lee JS, Lee HW, Kim BK, Kim MK, Kim HS, Park JY, Kim DY, Ahn SH, Lee BW, Kang ES, Cha BS, Lee Yh, Kim SU

Background/Aims: Nonalcoholic fatty liver disease (NAFLD) and obesity are independently associated with an increased risk for atherosclerotic cardiovascular disease (ASCVD), the leading cause of mortality in patients with NAFLD. Many...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Renal Tubular Damage Marker, Urinary N-acetyl-β-D-Glucosaminidase, as a Predictive Marker of Hepatic Fibrosis in Type 2 Diabetes Mellitus

Kim HK, Lee M, Lee Yh, Kang ES, Cha BS, Lee BW

Background: Non-alcoholic steatohepatitis is closely associated with the progression of diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM). We investigated whether urinary N-acetyl-β-D-glucosaminidase (u-NAG), an early renal tubular...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway

Lee JY, Lee M, Lee JY, Bae J, Shin E, Lee Yh, Lee BW, Kang ES, Cha BS

Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new class of antidiabetic drugs that exhibit multiple extraglycemic effects. However, there are conflicting results regarding the effects of SGLT2 inhibition on...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus

Bae J, Park T, Kim H, Lee M, Cha BS

Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and β-cell dysfunction. Among available oral antidiabetic agents, only the thiazolidinediones (TZDs) primarily target insulin resistance. TZDs improve insulin sensitivity...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Study on the Relationship between Sleep Quality and Cognitive Function in Community Elderly

Oh YK, Kim BJ, Park CS, Lee CS, Cha BS, Lee SJ, Lee DY, Seo JY, Lee YJ, Choi JW, Lee JH, Lee YJ

Objectives: Sleep disturbance in the elderly is associated with cognitive decline. Sleep quality is known to deteriorate with age, and prospective studies seldom have examined the relationship between sleep quality...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association

Lee BW, Lee Yh, Park CY, Rhee EJ, Lee WY, Kim NH, Choi KM, Park KG, Choi YK, Cha BS, Lee DH, Korean Diabetes Association (KDA) Fatty Liver Research Group

This clinical practice position statement, a product of the Fatty Liver Research Group of the Korean Diabetes Association, proposes recommendations for the diagnosis, progression and/or severity assessment, management, and follow-up...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus

Lee H, Kim G, Choi YJ, Huh BW, Lee BW, Kang ES, Cha BS, Lee EJ, Lee Yh, Huh KB

Background: Impaired diastolic heart function has been observed in persons with non-alcoholic fatty liver disease (NAFLD) and/or with type 2 diabetes mellitus (T2DM). However, it is unclear whether NAFLD fibrotic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Association Between Serum Bilirubin and the Progression of Carotid Atherosclerosis in Type 2 Diabetes

Lee I, Lee HH, Cho Y, Choi YJ, Huh BW, Lee BW, Kang ES, Park SW, Cha BS, Lee EJ, Lee YH, Huh KB

OBJECTIVE: This study investigated whether serum bilirubin levels can predict the progression of carotid atherosclerosis in individuals with type 2 diabetes mellitus (T2DM). METHODS: This observational study included 1,381 subjects with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Corrigenda: Table Correction. Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis

Lee YH, Cho Y, Lee BW, Park CY, Lee DH, Cha BS, Rhee EJ

In this article, the description of one equation named “NAFLD liver fat score” in the Table 3 was miswritten.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current Management of Type 2 Diabetes Mellitus in Primary Care Clinics in Korea

Seo DH, Kang S, Lee YH, Ha JY, Park JS, Lee BW, Kang ES, Ahn CW, Cha BS

BACKGROUND: This study investigated the overall status of diabetes control and screening for diabetic microvascular complications in patients with type 2 diabetes mellitus attending primary care clinics in Korea. METHODS: In...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial

Oh TJ, Yu JM, Min KW, Son HS, Lee MK, Yoon KH, Song YD, Park JY, Jeong IK, Cha BS, Kim YS, Baik SH, Kim IJ, Kim DM, Kim SR, Lee KW, Park JH, Lee IK, Park TS, Choi SH, Park SW

BACKGROUND: Combination of metformin to reduce the fasting plasma glucose level and an α-glucosidase inhibitor to decrease the postprandial glucose level is expected to generate a complementary effect. We compared...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Predictive Factors for Efficacy of AST-120 Treatment in Diabetic Nephropathy: a Prospective Single-Arm, Open-Label, Multi-Center Study

Hwang YC, Kim SW, Hur KY, Cha BS, Kim IJ, Park TS, Baik SH, Yoon KH, Lee KW, Lee IK, Lee MK

BACKGROUND: Removal of uremic toxins such as indoxyl sulfate by AST-120 is known to improve renal function and delay the initiation of dialysis in patients with advanced chronic kidney disease....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors

Lee JY, Cho Y, Lee M, Kim YJ, Lee YH, Lee BW, Cha BS, Kang ES

BACKGROUND: We investigated the predictive markers for the therapeutic efficacy and the best combination of sodium-glucose co-transporter 2 (SGLT2) inhibitors (empagliflozin, dapagliflozin, and ipragliflozin) therapy in patients with type 2...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment

Kim KS, Lee BW, Kim YJ, Lee DH, Cha BS, Park CY

Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders that are often comorbid conditions. Among many proposed treatments, weight reduction is the only approved option for NAFLD to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis

Lee YH, Cho Y, Lee BW, Park CY, Lee DH, Cha BS, Rhee EJ

Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders whose prevalence rates are expected to rise worldwide, corresponding to aging and increasingly obese populations. Compared to the general...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effects of Combination Therapy of Statin and Thiazolidinedione on Vascular Inflammation

Lee JY, Cha BS

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr